Compare Alphabet Inc Class A (GOOGL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Heron Therapeutics Inc — how do they compare? Alphabet Inc Class A trades at $342.21 (market cap $4.20T), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Alphabet Inc Class A is far larger — about 68326× Heron Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.26% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| GOOGL | HRTX | |
|---|---|---|
Market Cap | $4.20T | $61.47M |
Sector | Media | Health |
52-Week High | $402.62 | $1.49 |
52-Week Low | $199.32 | $0.32 |
Enterprise Value | $4.09T | $168.21M |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) is trading at $341.48, down 4.49% over the past 24 hours, with a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 85% analyst buy rating support the positive outlook, though technical indicators show near-term pressure with support at $341 and resistance at $350.
GOOGL presents a compelling long-term investment opportunity with robust profitability (54.77% net margin) and AI-driven growth potential, though investors face near-term technical weakness and regulatory risks. The consensus price target of $426.28 implies significant upside from current levels, supported by strong cash flow generation and strategic AI investments.
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
